Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway

Archives of Toxicology

Volumn 89, Issue 1, 2015, Pages 121-136

  Li, X ^a   Miao, H ^a   Zhang, Y ^a   Li, W ^a   Li, Z ^a   Zhou, Y ^a   Zhao, L ^a   Guo, Q ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bone marrow microenvironment; Oroxylin A; P gp; Soluble factor mediated drug resistance; Stat3

Indexed keywords

5,7-DIHYDROXY-6-METHOXY-2-PHENYLCHROMEN-4-ONE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CULTURE MEDIUM; FLAVONOID; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BONE MARROW; CELL PROLIFERATION; CHEMISTRY; CULTURE MEDIUM; CULTURE TECHNIQUE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; HUMAN; ISOLATION AND PURIFICATION; K562 CELL LINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; NUDE MOUSE; PATHOLOGY; PLANT ROOT; SCID MOUSE; SCUTELLARIA BAICALENSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BONE MARROW; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; PIPERAZINES; PLANT ROOTS; PYRIMIDINES; SCUTELLARIA BAICALENSIS; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940776788     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1226-6     Document Type: Article

References (35)

1. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA (2008) Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 7(10):3169–3175. doi:10.1158/1535-7163.MCT-08-0314
2. Bixby D, Talpaz M (2011) Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 25(1):7–22. doi:10.1038/leu.2010.238
3. Bournazou E, Bromberg J (2013) Targeting the tumor microenvironment: JAK-STAT3 signaling. Jak-Stat 2(2):e23828. doi:10.4161/jkst.23828
4. Caldera V, Mellai M, Annovazzi L, Valente G, Tessitore L, Schiffer D (2008) Stat3 expression and its correlation with proliferation and apoptosis/autophagy in gliomas. J Oncol 2008:219241. doi:10.1155/2008/219241
5. Coppo P, Flamant S, De Mas V et al (2006) BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 134(2):171–179. doi:10.1111/j.1365-2141.2006.06161.x
6. Cortes JE, Nicolini FE, Wetzler M et al (2013) Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk 13(5):584–591. doi:10.1016/j.clml.2013.03.020
7. Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11(7):1156–1166. doi:10.1101/gr.184901
8. Galimberti S, Cervetti G, Guerrini F et al (2005) Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Cancer Genet Cytogenet 162(1):57–62. doi:10.1016/j.cancergencyto.2005.01.015
9. Gao Y, Lu N, Ling Y et al (2010) Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation. J Cancer Res Clin Oncol 136(5):667–675. doi:10.1007/s00432-009-0705-2
10. Garrido SM, Appelbaum FR, Willman CL, Banker DE (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 29(4):448–457
11. Glowacki S, Synowiec E, Blasiak J (2013) The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors. Int J Mol Sci 14(8):16348–16364. doi:10.3390/ijms140816348
12. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167–1174. doi:10.1038/nm1483
13. Li HB, Chen F (2005) Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J Chromatogr A 1074(1–2):107–110
14. Litzow MR (2006) Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med 130(5):669–679. doi:10.1043/1543-2165(2006)130[669:IROAO]2.0.CO;2
15. Liu Y, Zhang SP, Cai YQ (2007) Cytoprotective effects of selenium on cadmium-induced LLC-PK1 cells apoptosis by activating JNK pathway. Toxicol In Vitro Int J Publ Assoc BIBRA 21(4):677–684. doi:10.1016/j.tiv.2007.01.015
16. Mahon FX, Hayette S, Lagarde V et al (2008) Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68(23):9809–9816. doi:10.1158/0008-5472.Can-08-1008
17. Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM (2012) Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012:157496. doi:10.1155/2012/157496
18. Melo JV, Chuah C (2008) Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. hematology/the education program of the American Society of Hematology American Society of Hematology Education Program. 427–435. doi:10.1182/asheducation-2008.1.427
19. Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA (2012a) Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leuk Res 36(6):756–763. doi:10.1016/j.leukres.2011.12.002
20. Nair RR, Tolentino JH, Hazlehurst LA (2012b) Role of STAT3 in transformation and drug resistance in CML. Front Oncol 2:30. doi:10.3389/fonc.2012.00030
21. Nambu T, Araki N, Nakagawa A et al (2010) Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Sci 101(1):137–142. doi:10.1111/j.1349-7006.2009.01365.x
22. Roecklein BA, Torok-Storb B (1995) Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 85(4):997–1005
23. Samanta A, Perazzona B, Chakraborty S et al (2011) Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25(3):463–472. doi:10.1038/leu.2010.287
24. Song X, Chen Y, Sun Y et al (2012) Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide. Pharmacol Rep PR 64(5):1189–1199
25. Sweet KL, Hazlehurst LA, Pinilla-Ibarz J (2013) The one-two punch: combination treatment in chronic myeloid leukemia. Crit Rev Oncol Hematol. doi:10.1016/j.critrevonc.2013.07.017
26. Traer E, MacKenzie R, Snead J et al (2012) Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 26(5):1140–1143. doi:10.1038/leu.2011.325
27. Traxler P (2003) Tyrosine kinases as targets in cancer therapy—successes and failures. Expert Opin Ther Targets 7(2):215–234. doi:10.1517/14728222.7.2.215
28. Wang H, Zhao L, Zhu LT et al (2013) Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1alpha and glycolysis, by inhibiting PI3 K/Akt signaling pathway. Mol Carcinog. doi:10.1002/mc.22052
29. Weisberg E, Wright RD, McMillin DW et al (2008) Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 7(5):1121–1129. doi:10.1158/1535-7163.MCT-07-2331
30. Yang HY, Zhao L, Yang Z et al (2012) Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-kappaB signaling pathway. Mol Carcinog 51(2):185–195. doi:10.1002/mc.20789
31. Zhang X, Xiao W, Wang L, Tian Z, Zhang J (2011) Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp. PLoS ONE 6(6):e20965. doi:10.1371/journal.pone.0020965
32. Zhang Y, Zhao L, Li X et al (2013) V8, a newly synthetic flavonoid, induces apoptosis through ROS-mediated ER stress pathway in hepatocellular carcinoma. Arch Toxicol. doi:10.1007/s00204-013-1085-6
33. Zhao L, Chen Z, Wang J et al (2010) Synergistic effect of 5-fluorouracil and the flavonoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemother Pharmacol 65(3):481–489. doi:10.1007/s00280-009-1053-2
34. Zhu B, Zhao L, Zhu L et al (2012) Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinbeta1 and its related pathway. Toxicol Appl Pharmacol 259(3):387–394. doi:10.1016/j.taap.2012.01.019
35. Zhu L, Zhao L, Wang H et al (2013) Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest. Toxicol Lett 219(2):107–115. doi:10.1016/j.toxlet.2013.01.019